Farallon Capital Management’s Sanofi Contingent Value Rights GCVRZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-9,195,584
| Closed | -$7.91M | – | 136 |
|
|
2019
Q4 | $7.91M | Buy |
9,195,584
+2,367,779
| +35% | +$1.82M | 0.05% | 102 |
|
|
2019
Q3 | $3.89M | Hold |
6,827,805
| – | – | 0.03% | 92 |
|
|
2019
Q2 | $3.55M | Hold |
6,827,805
| – | – | 0.02% | 96 |
|
|
2019
Q1 | $3.07M | Hold |
6,827,805
| – | – | 0.02% | 90 |
|
|
2018
Q4 | $3.28M | Hold |
6,827,805
| – | – | 0.02% | 90 |
|
|
2018
Q3 | $3.82M | Hold |
6,827,805
| – | – | 0.02% | 94 |
|
|
2018
Q2 | $3.41M | Hold |
6,827,805
| – | – | 0.02% | 86 |
|
|
2018
Q1 | $2.88M | Hold |
6,827,805
| – | – | 0.02% | 85 |
|
|
2017
Q4 | $2.6M | Hold |
6,827,805
| – | – | 0.02% | 80 |
|
|
2017
Q3 | $2.46M | Hold |
6,827,805
| – | – | 0.02% | 82 |
|
|
2017
Q2 | $2.6M | Hold |
6,827,805
| – | – | 0.03% | 78 |
|
|
2017
Q1 | $3.07M | Hold |
6,827,805
| – | – | 0.03% | 70 |
|
|
2016
Q4 | $2.6M | Buy |
6,827,805
+4,000,000
| +141% | +$1.35M | 0.03% | 68 |
|
|
2016
Q3 | $764K | Buy |
2,827,805
+33,000
| +1% | +$8.36K | 0.01% | 66 |
|
|
2016
Q2 | $671K | Buy |
2,794,805
+2,546,110
| +1,024% | +$438K | 0.01% | 64 |
|
|
2016
Q1 | $28K | Buy |
+248,695
| New | +$27K | ﹤0.01% | 75 |
|
|
2013
Q3 | – | Sell |
-1,320,000
| Closed | -$2.51M | – | 102 |
|
|
2013
Q2 | $2.51M | Buy |
+1,320,000
| New | +$2.32M | 0.05% | 76 |
|
Farallon Capital Management's GCVRZ Position: Q1 2020 in Review
Farallon Capital Management sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2020, closing a stake of 9,195,584 shares — an estimated $7.91M sold.
Farallon Capital Management first reported a position in GCVRZ in Q2 2013 and held it in 17 quarters. The position peaked at $7.91M in Q4 2019. 2 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2020.
- Farallon Capital Management reported no remaining Sanofi Contingent Value Rights position as of Q1 2020 after selling out during the quarter.
- Farallon Capital Management sold 9,195,584 Sanofi Contingent Value Rights shares in Q1 2020, an estimated $7.91M.
- Farallon Capital Management first reported a position in Sanofi Contingent Value Rights in Q2 2013 and held it in 17 quarters.
- Farallon Capital Management's Sanofi Contingent Value Rights position peaked at $7.91M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2020.
Based on Farallon Capital Management's 13F filing for Q1 2020, filed 15 May 2020.